MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a case study outlining the successful collaboration between it and Anglo-Swedish drug major AstraZeneca (LSE: AZN) on a £120 million ($188 million) facility in Macclesfield to manufacture important treatments for prostate and breast cancer.

The MHRA cited offering regulatory and scientific advice to companies in the early stages of medical developments as being the basis of innovative technologies such as this. AstraZeneca could access guidance and advice from MHRA to help them navigate the requirements in developing the Macclesfield facility.

Gerald Heddel, director of inspection, enforcement and standards division at the MHRA, said: “We at MHRA welcome early approaches from companies who need access to expert knowledge, guidance and experience of regulatory processes. As well as being a regulator, we also recognize the importance of supporting companies in their planning processes, in order to ensure positive outcomes for public health.”